Skip to main content
OpenTrials

Clinical trial condition

Hematologic Diseases

Explore clinical trials studying Hematologic Diseases. Study availability and eligibility vary by location and protocol.

15,526 public trials 2,840 recruiting studies
Refine in advanced search Browse all conditions

Hematologic Diseases trial results

Completed

Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

NCT04666259

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myelogenous Leukemia - Chronic Phase, +12 more
Locations
  • Alaska Oncology and Hematology Anchorage, Alaska, United States
  • Arizona Oncology Associates Phoenix, Arizona, United States
  • Cancer Treatment Centers of America Phoenix, Arizona, United States
  • Pacific Shores Medical Group Long Beach, California, United States
View all 26 locations
View Trial Details
Completed

Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

NCT03474965

Conditions
Anemia, Anemia, Hemolytic, Anemia, Hemolytic, Congenital, +19 more
Locations
  • University Of Alabama Birmingham, Alabama, United States
  • Childrens National Hospital Washington D.C., District of Columbia, United States
  • University of Florida Gainesville, Florida, United States
  • Joe DiMaggio Childrens Hospital Hollywood, Florida, United States
View all 35 locations
View Trial Details
Completed

Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

NCT02512926

Conditions
Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +10 more
Locations
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Stanford University School of Medicine and Stanford Cancer Institute Palo Alto, California, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT05105841

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia (CLL), Disease Attributes, +15 more
Locations
  • Duplicate_NHO Nagoya Medical Center /ID# 233523 Nagoya, Aichi-ken, Japan
  • Aichi Cancer Center Hospital /ID# 238797 Nagoya, Aichi-ken, Japan
  • Duplicate_Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524 Nagoya, Aichi-ken, Japan
  • Duplicate_Chiba Cancer Center /ID# 238839 Chiba, Japan
View all 20 locations
View Trial Details
Completed

IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation

NCT03515512

Conditions
Acute Myeloid Leukemia, Bone Marrow Diseases, Chronic Disease, +13 more
Locations
  • Johns Hopkins Cancer Center Baltimore, Maryland, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details
Completed

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT04540796

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
  • Austin Hospital Heidelberg, Australia
View all 32 locations
View Trial Details

Related conditions